Pulmonary deposition of inhaled drugs
|
|
- Darcy Sutton
- 6 years ago
- Views:
Transcription
1 Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy
2 Presenter Disclosures F.L. has received in the last 5 years fees for lectures, advisory boards and reimbursements for attending meetings from the following pharma companies: - AstraZeneca, - Boehringer Ingelheim, - CIPLA, - Chiesi, - Mundipharma, - TEVA. The content of this talk represents the personal opinion of the presenter and does not necessarily represent the views or policy of the A.O.U. Careggi.
3 The efficacy by which inhaled drug particles reach the target site in the lung is determined by: Throat deposition Penetration of the particles into the airways Sedimentation Deposition of the particles on the wall of the airways Exhalation Deposition is the process by which an aerosol particle leaves the airstream and is retained on the epithelium Bisgaard H, O Callaghan C, Smaldone GC. Drug delivery to the Lungs, 2002
4 Factors Influencing the Lung Deposition of Medical Aerosols Aerosol Characteristics Particle size Particle density Particle charge Aerosol plume speed & duration Lipophilicity Hygroscopicity Patient Factors Inhalation technique - Inspired volume - Inspiratory flow - Breath hold pause Airway disease & severity Device acceptance Compliance Labiris & Dolovich, Br J Clin Pharm 2003
5 Factors Influencing the Lung Deposition of Medical Aerosols Aerosol Characteristics Particle size Particle density Particle charge Aerosol plume speed & duration Lipophilicity Hygroscopicity Patient Factors Inhalation technique - Inspired volume - Inspiratory flow - Breath hold pause Airway disease & severity Device acceptance Compliance Labiris & Dolovich, Br J Clin Pharm 2003
6 1: PARTICLE SIZE But before we get started.... Some terms used to describe an aerosol
7 Aerosol particles can be considered small spheres with a diameter and a density. Mass Median Aerodynamic Diameter (MMAD) is defined as the diameter at which 50% of the particles are larger and 50% are smaller. Geometric Standard Deviation (GSD) is a measure of the spread of an aerodynamic particle size distribution. MMAD
8 Monodisperse aerosol: particles with the same size (GSD<1.2).Example: laboratory generated aerosols Polydisperse aerosol: particles include a widerange of sizes (GSD >1.2). Example: therapeutic medications range from 2-3 Fine Particle Fraction (FPF): The proportion of particles within the aerosol with MMAD <5 µm, or fine particle dose if expressed in absolute mass of drug in particle with MMAD<5 µm.
9 MMAD, GSD, FPF are the most frequently used terms to describe an aerosol Andersen Cascade Impaction Aerodynamic Particle Size Distribution A series of 8 stages reflecting the progressive decreasing in size of the airways
10 Inhaled dose
11 Deposition: main mechanisms - Inertial transport (impaction): large particles (6-10 μm); high flow velocity; mainly in the upper and large airways. - Gravitational transport (sedimentation): small particles (0.5-6 μm); low flow velocity; timedependent transport mechanism; mainly in the lung periphery lower generations where the velocity is low and airway is small. - Diffusional transport (diffusion): very small particles (< 0.5 μm); low flow velocity; timedependent transport mechanism; mainly in the alveoli due to long residence time. Courtesy by AH de Boer
12 Sedimentation takes time Sedimentation (under influence of the force of gravity) takes time and the stationary settling velocity decreases with the square of the diameter The time necessary to fall a distance of 0.5 mmm for a particle of: 1 µm is 16.5 s 2 µm is 4.2 s 4 µm is 1,0 s
13 Relationship between the impaction parameter and the oropharyngeal deposition Oropharyngeal deposition becomes higher when the flow rate is increased and the effect is greater for larger particles Recalculated from: Usmani et al., Am J Respir Crit Care Med 2005; 172:
14 Particle size: Summary Inertial impaction in the larger airways depends on particle diameter (D) and particle flow rate ( ), Sedimentation in the smaller airways depends on particle diameter (D) and particle residence time
15 Where do most inhaled aerosols deposit in the healthy human adult male respiratory tract? «Respirable range» Chrystyn, Allergy 1999
16 Patient with cystic fibrosis after inhalation of 7- and 3-μm radiolabelled carbenicillin aerosols
17 Gamma camera images of 99m Tclabelled salbutamol monodisperse aerosols in one asthma patient. 1.5µm 3µm 6µm 1.5µm 3µm 6µm 1,5 μm Posterior thorax 3,0 μm 6,0 μm Smaller Particles = Good Lung & Peripheral Deposition; Low Oropharyngeal Deposition
18 % Regional Lung Deposition Small Particles = High Total Lung Deposition 75 Central (C) + Intermediate (I) Zone Peripheral Zone (P) 50 TLD µm 3µm 6µm 0 Usmani, AJRCCM 2005 Small Particles = Better Peripheral Deposition
19 % Deposition Small Particles = Low Oropharyngeal Deposition * 1.5µm 3µm 6µm * * * Oro-P * * 0 Lung O Lung O Lung O O = Oropharyngeal * p<0.05 Usmani, AJRCCM 2005
20 % Deposition % Deposition Small Particles = Exhaled less vs. in vitro data µm 3µm 6µm 1.5µm 3µm 6µm * * * L O E L O E L O E * L Total Lung Deposition, O Oropharyngeal, E Exhaled * * * p< p<0.05 Usmani, AJRCCM 2005
21 2. Aerosol plume speed & duration
22 Duration [s] Respimat: aerosol characteristics Velocity at 10 cm distance from orifice [m/s] 1,6 1,4 Respimat Duration 10 9 Velocity 1,2 1, HFA-MDI CFC-MDI 0,8 5 0,6 4 0,4 0,2 HFA-MDI CFC-MDI Respimat 0,0 0 Hochrainer Hochrainer et et al al J J Aerosol Aerosol Med Med Respimat may reduce the need of hand-breath coordination!
23 Proportion of emitted dose (%) Particle size distribution for Respimat ~ 45% in the range < < < < < < < < <10.0 ³10.0 Andersen cascade impactor data Fine particle range (µm) Zierenberg B. J Aerosol Med 1999
24 Lung Deposition se (% dose) Lungs Oropharynx Device Exhaled 20 0 Respimat pmdi + spacer
25 Drug delivery to the lungs with Respimat is more efficient than with HFA-pMDI, even in patients with poor inhaler technique.
26 3. Airway disease & severity
27 Total deposition of particles is increased in patients with obstructive airway disease, and correlates with FEV 1.
28 Quiet breathing Flow limitation 6 subjects with induced flow limitation Regional deposition patterns is affected by airway obstruction with a shift of particles deposition from lung periphery towards proximal airways.
29 Particles deposition is less uniform with enhanced focal distribution («hot spots») of deposited particles with increasing dose of metahcoline (MCh).
30 Small Particles (MMAD 1.5µm) Achieve Consistent Lung Deposition in Varying Airflow Obstruction De Backer, JAMPDD 2010 Healthy Asthma COPD FEV 1 112% pred) FEV 1 71% pred) FEV 1 44% pred) 34% 31% 33% Scintigraphic images show consistency in lung deposition in different disease groups
31 4: BREATHING PATTERN & INHALATION MANOUVRE
32 Breathing pattern harldy affects the shape of the deposition curve, but it can shift the curve up and down affecting deposition values across the entire range of particle size.
33 Fixed f (15 breaths/min) Fixed Q (250 ml/s) Particles 3 and 5 μm: total deposition increases by rising VT; Particles 1 μm: total deposition unaffected by VT increases; Particles 1-5 μm: total deposition increases by rising both VT and f;
34 Deposition shifts to larger airways when the flow rate is increased Deposition fraction Airway generation PR Byron: Respiratory Drug Delivery. CRC Boca Raton 1990; 1 38.
35
36
37 Crucial differences between device types
38 Deposition (% emitted dose) Lung deposition of small-particle aerosol under coordinated and dis-coordinated conditions N=7 asthmatics, FEV 1 91% pred. Lung Oropharynx pmdi pmdi pmdi ON TIME EARLY LATE Leach et al J Aerosol Med 2005
39 % Total Lung Deposition (TLD) Small Particles = Less Affected by Inhalation Flow 75 FAST: >60 litres/ min = SLOW: litres/ min 50 * TLD 25 * p< µg dose 1.5µm 3µm 6µm Slow Fast Slow Fast Slow Fast SLOW Inhalation is better Usmani, AJRCCM 2005
40 Δ FEV 1 (ml) Inhalation flow rate can affect clinical outcomes Patients with stable, mild-to-moderate asthma (n=12) Monodispersed salbutamol aerosols of three different diameters 750 p < 0.05 p < 0.05 p < Slow inhalation Fast inhalation μm 3.0 μm 6.0 μm Aerosol diameter Usmani et al. Am J Respir Crit Care Med 2005; 172:
41 Crucial differences between device types
42 Powder formulations are always agglomerated (particles 1 5 m) Adhesive mixtures Soft (spherical) agglomerates/pellets Frijlink & de Boer. Expert Opinion on Drug Delivery 2004; 1(1): 67-86
43 Particle emission from a DPI and the inhalation flow Inhalation flow Dose emission from a reservoir DPI Patient s inhalation flow Profile through a DPI Each inhalation should be as fast as you can from the start and for as long as possible Dose emission from a capsule DPI Time Adapted from Bisgaard et al Eur Respir J 1998
44 DPI OPERATING PRINCIPLE Airflow Generated By Patient s Inspiratory Effort Inspiratory Force Flow & Pressure De-aggregation Fine Particle Mass Drug Lactose Turbulent Energy: P = Q x R Q = Inhalation Flow R = Inhaler resistance..for an inhaler with a low resistance you need a very high inhalation flow whereas for a higher resistance you need a low inhalation flow... Chrystyn et al. Am J Respir Crit Care Med 2001
45 Inspiratory flow resistance (kpa 0.5 L/min -1 ) Inspiratory flow rate (L/min) Inhaler resistance and the corresponding flow to achieve 4 kpa pressure drop
46 Flow rate (L/min) Breezhaler Diskusr Aerolizer ELLIPTA Inhaler resistance + Genuair Turbohaler NEXThaler Twisthaler Q = Easyhaler 1 R inh dp dp = Q X R inh HandiHaler Pressure drop (kpa) Inspiratory flow Pressure drop Inhaler resistance..with a low resistance inhaler you need a higher inhalation flow than with a high resistance inhaler. Modified from Al-Showair et al Resipr Med 2007; P. Krüger et al ERS meeting 2014
47 Fine Particle Dose (%) DPI Lung Dose Alters with Inhalation Flow Turbuhaler Aerolizer Accuhaler 10 THROAT DEPOSITION Inhalation Flow (l/min) In vitro data do not necessarily correlate with clinical effectiveness Palander, Clin Drug Invest 2000; Weuthen, J Aerosol Med 2002
48 Mean delivered ICS fine particle fraction (FPF) as function of kpa (in vitro) DPI Resistanc e Flow rate (4 kpa) (kpa 0.5.min.L - 1 ) (L/min) Turbuhaler NEXThaler Ellipta* 0, ,5 Diskus # # # # * Similar results for 2 -agonist Elpenhaler #, data from 1;*, data from 2 In vitro data do not necessarily correlate with clinical effectiveness Adapted from: 1 De Boer et al. Eur J Pharm Biopharm 2015; 2 Grant A et al JAMPDD 2015.
49 Let s classify DPIs Inhalation flow dependent High - intermediate resistance Turbuhaler Diskus Inhalation flow dependent Low resistance Pulvinal Jethaler Easyhaler Inhalation flow independent High-intermediate resistance Novolizer Cyclohaler Aerolizer Handihaler Inhalation flow independent Low resistance Diskhaler Aerohaler Clickhaler Spinhaler Gyrohaler Pictures from ADMIT homepage
50 Effect of different flows on airway deposition: an invitro study comparing Diskus vs Novolizer With Diskus the central and peripheral deposition decreases when the flow is increased. With Novolizer the central and peripheral deposition remains fairly constant at all flow rates. Courtesy by A.H. De Boer
51 Delivered dose (µg) Delivered dose (µg) 100 Beclomethasone Dipropionate Formoterol L 4L Flow rate (L/min) Flow rate (L/min) 0
52 SUMMARY The advantages of pulmonary delivery of aerosolized therapeutic drugs have resulted in many classes of drugs and inhalers now available for this route of delivery. However, there are many challenges to optimizing delivery of aerosolized drugs by the pulmonary route. Be aware of the effect of particle size on pulmonary aerosol deposition. Understand the needo for specific inhalation maneuvers to optimize pulmonary delivery of therapeutic medications with available devices.
53 THANKS FOR YOUR KIND ATTENTION Questions? That s a great question!! Come to think of it, I m not sure what it is I was trying to tell you
54
55
56
57 Regional deposition patterns is altered with increasing severity of airway obstruction healthy subject Patients with various degrees of airway obstruction FEV = 25% FEV = 45% FEV 1 = 50% FEV = 60% Laube BL et al Respiratory Care 2005
21/03/2011 AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY. Fundamentals of aerosols
AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY Steve Newman Scientific Consultant Norfolk, UK steve.newman@physics.org
More informationCAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing
More informationWhat you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG
What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG VM The authors describe the problems that arise with metered-dose and dry-powder inhalers,
More informationCLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA. Steve Newman, PhD Nottingham, UK November 2006
IPAC-RS Conference 6-8 November 2006 CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA Steve Newman, PhD Nottingham, UK November 2006 IPAC-RS Conference 6-8 November 2006 1 EFFECT OF PARTICLE SIZE ON
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationAdvanced Inhaler Technique. Learning Outcomes. Disclosure 1.1. Belgian Chocolate, French Champagne and Inhaled Medication: Too Good To Waste?
Advanced Inhaler Technique Learning Outcomes Describe the mechanism of different inhalers Explain how inspiratory flow can effect drug delivery for different inhalers Counsel a patient on the correct use
More informationThe problem with critical and non-critical inhaler errors
The problem with critical and non-critical inhaler errors Federico Lavorini MD, PhD Dept. Experimental and Clinical Medicine Careggi University Hospital Florence, Italy Presenter disclosures Federico Lavorini
More informationA multitude of devices
A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless
More informationPatricia KP Burnell Inhalation Product Development
Patricia KP Burnell Inhalation Product Development Inhaled products: types, development The critical parameters In-vitro testing Ex-vivo testing What dose? Product Development: drug medicine Safety and
More informationInhalers and nebulizers: basic principles and preliminary measurements
Inhalers and nebulizers: basic principles and preliminary measurements Ondrej Misik 1*, Frantisek Lizal 1, Vahid Farhikhteh Asl 2, Miloslav Belka 1, Jan Jedelsky 1, Jakub Elcner 1 and Miroslav Jicha 1
More informationCOPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?
Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes
More informationThe Use of Physics-Based Modeling to Better Design Drug- Device Interface. Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ
The Use of Physics-Based Modeling to Better Design Drug- Device Interface Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ Presentation Outline Physics-based modeling in pharmaceutical industry Pulmonary
More informationAssessing Quality of Inhaled Products And Links to Efficacy and Safety
Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation
More informationHigher lung deposition with Respimat Soft Mist Inhaler than HFA-MDI in COPD patients with poor technique
ORIGINAL RESEARCH Higher lung deposition with Respimat Soft Mist Inhaler than in COPD patients with poor technique Peter Brand 1 Bettina Hederer 2 George Austen 3 Helen Dewberry 3 Thomas Meyer 4 1 RWTH,
More informationAEROSOL THERAPY: THE PRACTICALITIES
AEROSOL THERAPY: THE PRACTICALITIES Lester I. Harrison, PhD Section Head, Clinical Pharmacokinetics, 3M Pharmaceuticals, 3M Center 270-3S-05, St. Paul, MN, USA 55144 liharrison@mmm.com Introduction: Horses,
More informationDry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationInhalation Therapy. Inhalation Therapy
Matching Device and Patient Matching Patient to the Device Søren Pedersen University of Southern Denmark Kolding Hospital Anatomical factors (age) Training and education Delivered dose Psycomotor skills
More informationEXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION
EXPERT OPINION: REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION The inhalation route is a fast and effective way of delivering medication, both locally to the
More informationInh l a t a i tional D i ev ces for the Ou O t u pat p ie i nts Dr Sunil Sharma Senior Resident
Inhalational ldevices for the Outpatients Dr Sunil Sharma Senior Resident Introduction Inhalational ltherapy allows selective treatment t tof lungs achieving high concentrations in airway minimizing systemic
More informationInhaler Standards and Competency Document
Inhaler Standards and Competency Document Inhaler Standards and Competency Document Authors: Jane Scullion Respiratory Nurse Consultant University Hospitals of Leicester NHS Trust Monica Fletcher CEO of
More informationFRI aerosol. deposition. A unique way to look at regional inhaled drug deposition.
FRI aerosol deposition A unique way to look at regional inhaled drug deposition www.fluidda.com EXECUTIVE SUMMARY FRI - AN UPDATE OF SCINTIGRAPHY FRI deposition technology is based on CT imaging, and uses
More informationCOMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES
COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation
More informationFarmaci inalatori e dispnea nell asma e nella BPCO. Federico Lavorini
Farmaci inalatori e dispnea nell asma e nella BPCO Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the
More informationPatient adherence to inhaled therapy A clinical perspective. Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France
Patient adherence to inhaled therapy A clinical perspective Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France 1 Disclosures Aerocrine Almirall AstraZeneca Boehringer Ingelheim
More informationUniversity of Groningen. Optimisation of dry powder inhalation Boer, Anne Haaije de
University of Groningen Optimisation of dry powder inhalation Boer, Anne Haaije de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationIVIVC in Pediatric OIPs
IPAC-RS/UF Orlando Conference 2014 March 20, 2014 IVIVC in Pediatric OIPs Herbert Wachtel Declaration of Conflicts of Interest H. Wachtel is employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationFRI aerosol. deposition. A unique way to look at regional inhaled drug deposition.
FRI aerosol deposition A unique way to look at regional inhaled drug deposition www.fluidda.com EXECUTIVE SUMMARY Since 2005, Functional Respiratory Imaging (FRI) has been used many times to evaluate the
More informationRDD Europe 2009 Workshop
RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution. An Introduction to Differentiating
More informationThe optimal particle size for beta-adrenergic aerosols in mild asthmatics*
The optimal particle size for beta-adrenergic aerosols in mild asthmatics* Introduction The treatment of asthma and chronic obstructive pulmonary diseases (COPD) has improved considerably with the introduction
More informationOF COATING MATERIAL ON THE AERODYNAMIC PARTICLE SIZE DISTRIBUTION (PSD) OF OXIS TURBOHALER USING MIXING INLET WITH AN ANDERSEN CASCADE IMPACTOR (ACI)
165 J App Pharm 2(3): 165-178 (2011) Khan et al., 2011 EFFECT OF COATING MATERIAL ON THE AERODYNAMIC PARTICLE SIZE DISTRIBUTION (PSD) OF OXIS TURBOHALER USING MIXING INLET WITH AN ANDERSEN CASCADE IMPACTOR
More informationINHALATION DRUG DELIVERY DEVICES: BRONCHODILATORS NATTAWAT NATPHOBSUK, MD
INHALATION DRUG DELIVERY DEVICES: BRONCHODILATORS NATTAWAT NATPHOBSUK, MD BACKGROUND SHORT-ACTING 2 -AGONISTS SHORT-ACTING 2 -AGONISTS (SABAS) USED EXTENSIVELY IN THE MANAGEMENT OF PULMONARY DISEASES SINCE
More informationUniversity of Groningen. Technology in practice Lexmond, Anne
University of Groningen Technology in practice Lexmond, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationDry powder inhalation de Boer, Anne; Hagedoorn, Paul; Hoppentocht, Marcel; Buttini, F; Grasmeijer, F.; Frijlink, H.W.
University of Groningen Dry powder inhalation de Boer, Anne; Hagedoorn, Paul; Hoppentocht, Marcel; Buttini, F; Grasmeijer, F.; Frijlink, H.W. Published in: Expert Opinion on Drug Delivery DOI: 10.1080/17425247.2016.1224846
More informationThe inhaled route is preferred for the
Eur Respir Rev 2005; 14: 96, 102 108 DOI: 10.1183/09059180.05.00009605 CopyrightßERSJ Ltd 2005 Inhaler treatment options in COPD S.P. Newman ABSTRACT: A variety of inhaler devices are available for delivering
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationAirway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers
Eur Respir J 1997; 10: 2127 2138 DOI: 10.1183/09031936.97.10092127 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 REVIEW Airway deposition
More informationPocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals
Pocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals Endorsed by NHSGGC Respiratory Managed Clinical Network; June 2016 Designed by Medical Illustration Services Contents
More informationAn update on inhalation devices
OPTIMIZING INHALED DRUG DELIVERY An update on inhalation devices Contents 1. Introduction...1 2. History of spacers... 1 3. Working of a spacer... 2 4. Advantages of spacer devices... 3 5. Who should
More informationDevice Design Similarity
Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity
More informationPractical Problems With Aerosol Therapy in COPD. Joseph L Rau PhD RRT FAARC
Special Articles Practical Problems With Aerosol Therapy in COPD Joseph L Rau PhD RRT FAARC Introduction Problems With Use of MDIs Synchronizing Inhalation With MDI Actuation Lack of a Dose Counter Medical
More informationLung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs)
European Review for Medical and Pharmacological Sciences 2017; 21: 2708-2716 Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs)
More information2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus
2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus Patient Perspective Alpha-1 1 Foundation John W. Walsh Patient Focus Personal perspective Challenges and lessons Importance
More informationEquivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi)
Respiratory Drug Delivery Europe 2017 Nagel and Suggett Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi) Mark W. Nagel and Jason A. Suggett
More informationAdapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016
Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies Julie D. Suman, Ph.D. March 29, 2016 AGENDA Regulatory Approaches for Bioequivalence (BE) Compendial Testing Vs Pharmaceutical Equivalence
More informationPaediatric pulmonary drug delivery: considerations in asthma treatment
Review Paediatric pulmonary drug delivery: considerations in asthma treatment 1. Introduction 2. Guideline recommendations 3. Factors affecting drug delivery to the lung 4. Nebulisers 5. Metered-dose inhalers
More informationWhat Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation
What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects Jolyon P. Mitchell, Ph.D. Trudell Medical International London, Canada IPAC-RS Conference November 2006 1 Context of Presentation This talk
More informationL. Borgström*, E. Bondesson*, F. Morén**, E. Trofast*, S.P. Newman +
Eur Respir J, 1994, 7, 69 73 DOI: 10.1183/09031936.94.07010069 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 0903-1936 Lung deposition of budesonide
More informationPeak inspiratory flow through the Genuair â inhaler in patients with moderate or severe COPD
Respiratory Medicine (9) 13, 1832e1837 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Peak inspiratory flow through the Genuair â inhaler in patients with moderate or
More informationUse of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung
Use of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung Nia Stevens 9 th November 2016 Thanks to Richard Kaye, James Mitchell, Dave Prime at GSK Bahman Asgharian and Owen
More informationMetered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC
Metered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC William H. Doub, Ph.D. Division of Pharmaceutical Analysis (DPA) US FDA/CDER/OPS/OTR The information presented
More informationUse of Respimat Soft Mist Inhaler in COPD patients
REVIEW Use of Respimat Soft Mist Inhaler in COPD patients Paula Anderson Division of Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, Central Arkansas Veterans Healthcare
More informationScintigraphic comparison of budesonide deposition from two dry powder inhalers
Eur Respir J 2000; 16: 178±183 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Scintigraphic comparison of budesonide deposition from two
More informationFig 1. How to use the In-Check M. Clinically Effective Flow Rate L/Min
Fig 1. How to use the In-Check M 1 2 3 4 5 6 Clinically Effective Flow Rate 30-60 L/Min 1 Instructions for Use Consult Instructions for Use. Introduction The In-Check M is an inhalation airflow meter that
More informationUniversity of Huddersfield Repository
University of Huddersfield Repository Azouz, Wahida Ahmed Abugrara Novel methodology to characterise how asthma and chronic obstructive pulmonary disease patients use their inhalers and methods to improve
More informationUnderstanding cascade impaction and its importance for inhaler testing
Understanding cascade impaction and its importance for inhaler testing Mark Copley, Technical Sales Manager Inhalation product development is an important area of activity for the pharmaceutical sector.
More informationChapter 1 Pulmonary drug delivery
Chapter 1 Pulmonary drug delivery Pulmonary drug delivery 1.1 Introduction The respiratory tract is an attractive route for the administration of therapeutics and genomics. The past decade has been marked
More informationDr Michael Ho AGENDA. Asthma control requires treating underlying pathophysiology. The goal of asthma management To achieve overall asthma control
Dr Michael Ho Consultant Respiratory & Sleep Physician Dandenong Respiratory Group Director of South Eastern Private Sleep Centre Part 1 AGENDA Generalised asthma management: Stepwise approach Part 2 Inhaler
More informationMisty Max 10 nebulizer
AirLife brand Misty Max 10 nebulizer Purpose Introduction Delivery of nebulized medication to the lungs is a complex process dependant upon a variety of clinical and device-related variables. Patient breathing
More informationNovolizer Technical Aspects
Novolizer Technical Aspects Dr José Mª Negro Alvarez H.U. Virgen de la Arrixaca.. Murcia (España) a) Profesor Asociado de Alergología. Universidad de Murcia (España) a) Contents Design and function of
More informationCitation for published version (APA): Koning, J. P. D. (2001). Dry powder inhalation: technical and physiological aspects, prescribing and use s.n.
University of Groningen Dry powder inhalation Koning, Johannes Petrus de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationCan all patients with COPD use the correct inhalation flow with all inhalers and does training help?
Respiratory Medicine (27) 11, 2395 241 Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Raid A.M. Al-Showair a, Walid Y. Tarsin a, Khaled H. Assi a,
More informationAsthma Control: The Right Inhaler for the Right Patient
Adv Ther (2015) 32:285 292 DOI 10.1007/s12325-015-0201-9 REVIEW Asthma Control: The Right Inhaler for the Right Patient Nicola Scichilone To view enhanced content go to www.advancesintherapy.com Received:
More informationABSTRACT. Keywords: Budesonide; Delivered dose; Dry powder inhaler (DPI); Fine particle dose; Formoterol; Inhaler device ORIGINAL RESEARCH
Pulm Ther (2017) 3:243 253 DOI 10.1007/s41030-017-0042-6 ORIGINAL RESEARCH Impact of Inhalation Flow, Inhalation Volume and Critical Handling Errors on Delivered Budesonide/Formoterol Dose in Different
More informationInstructions for Use. Engineered for Life
Instructions for Use Engineered for Life Instructions for Use Consult Instructions for Use. This product complies with the essential requirements of the medical devices directive (93/42/EEC). Compliance
More informationJAMES B. FINK, RAJIV DHAND, JERRY GRYCHOWSKI, PATRICK J. FAHEY, and MARTIN J. TOBIN
Reconciling In Vitro and In Vivo Measurements of Aerosol Delivery from a Metered-Dose Inhaler during Mechanical Ventilation and Defining Efficiency-enhancing Factors JAMES B. FINK, RAJIV DHAND, JERRY GRYCHOWSKI,
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationImproved Aerosol Deposition Profiles from Dry Powder Inhalers
1 University of Hertfordhire Improved Aerosol Deposition Profiles from Dry Powder Inhalers Submitted to the University of Hertfordshire in partial fulfilment of the requirements of the degree of Doctor
More informationEffect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients
Thorax 1987;42:457-461 Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma D M MITCHELL, M A SOLOMON, S E J TOLFREE, M SHORT,
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationAsthma in Day to Day Practice
Asthma in Day to Day Practice VIJAY.K.VANAM Financial relationships: Disclosures Employed at Mercy Medical Center, Mason City. Nonfinancial relationships: I receive no financial gain from any pharmaceutical
More informationThe ideal inhaler: design and characteristics to improve outcomes
Respiratory Medicine (2004) Supplement A, S10 S16 ARTICLE IN PRESS The ideal inhaler: design and characteristics to improve outcomes Brian J. O Connor* Department of Respiratory Medicine and Allergy, Guy
More informationCOPD Education for Clinic RNs and MA s 6/28/18
COPD Education for Clinic RNs and MA s 6/28/18 Objectives Define Chronic Obstructive Disease (COPD) Diagnosis of COPD Review recommended therapies for COPD. Teach-Back OSA and it s impact. I want to interact
More informationDry powder inhalers for pulmonary drug delivery
Review Dry powder inhalers for pulmonary drug delivery HW Frijlink & AH De Boer Department of Pharmaceutical Technology and Biopharmacy, Groningen University Institute for Drug 1. Introduction 2. The target
More informationProf. Dr. Henderik W. Frijlink
Pulmonary drug administration technologies to improve the therapy in Asthma, COPD and beyond. Prof. Dr. Henderik W. Frijlink Department of Pharmaceutical Technology and Biopharmacy University of Groningen
More informationAchieving asthma control: the key role of inhalers
The ERS designates this educational activity for a maximum of 1 CME credit. For information on how to earn CME credits, see page 190 Achieving asthma control: the key role of inhalers Educational aims
More informationPharmacokinetics, pharmacodynamics, and the delivery of pediatric bronchodilator therapy
Pharmacokinetics, pharmacodynamics, and the delivery of pediatric bronchodilator therapy David P. Skoner, MD Pittsburgh, Pa β 2 -adrenergic receptor agonists have long been used for the amelioration of
More informationDelivering Aerosol Medication in ICU
Delivering Aerosol Medication in ICU 18th Aug 2017 Lau Chee Lan Pharmacist HCTM PPUKM ASMIC 2017 Aerosol Therapy Part of the treatment for a variety of respiratory disease * asthma and chronic obstructive
More informationAssessing the role of breathing simulators in OIP testing
As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can
More informationInhaler Devices for Delivery of LABA/LAMA Fixed- Dose Combinations in Patients with COPD
https://doi.org/10.1007/s41030-019-0090-1 REVIEW Inhaler Devices for Delivery of LABA/LAMA Fixed- Dose Combinations in Patients with COPD Anthony D Urzo. Kenneth R. Chapman. James F. Donohue. Peter Kardos.
More informationDeposition of Inhaled Particle in the Human Lung for Different Age Groups
Deposition of Inhaled Particle in the Human Lung for Different Age Groups Xilong Guo 1, Qihong Deng 1* 1 Central South University (CSU), Changsha, China * Corresponding email: qhdeng@csu.edu.cn, qhdeng@gmail.com.
More informationINHALER DEVICES: THE PAST, THE PRESENT, AND THE FUTURE
INHALER DEVICES: THE PAST, THE PRESENT, AND THE FUTURE This symposium took place on 27 th September 2015, as part of the European Respiratory Society International Congress 2015 in Amsterdam, Netherlands
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationTransactions on Biomedicine and Health vol 2, 1995 WIT Press, ISSN
Biomedical application of the supercomputer: targeted delivery of inhaled Pharmaceuticals in diseased lungs T.B. Martonen,* I. Katz,* D. Hwang,' Y.Yang* "Health Effects Research Laboratory, U.S.Environmental
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationBreakout Session # A 12:45 1:25. New Methods of Medication Delivery to the Lungs: Say Goodbye to the MDI as we know it
Breakout Session # A 12:45 1:25 New Methods of Medication Delivery to the Lungs: Say Goodbye to the MDI as we know it Michael J. Welch MD, FAAP, FAAAAI, CPI Co-director, Allergy & Asthma Medical Group
More informationNEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS
NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationDisclosures. Learning Objectives 3/25/2017. Novel Inhalers for COPD and Asthma
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Novel Inhalers for COPD and Asthma Dennis Williams, PharmD., BCPS. AE-C Associate Professor
More informationRespiratory Therapy. Medical/Scientific/General Background
Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM
More informationIMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING
IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING In this piece, Mark Copley, Sales Director of Copley Scientific, provides some background on mouth-throat models for
More informationYour Inhaler Devices & You
1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE
More informationSmall Airways : How To Confident Diagnosis and Management?
Small Airways : How To Confident Diagnosis and Management? Assistant Prof. Siwasak Juthong. M.D. Division of Respiratory and Respiratory Critical Care Medicine Faculty of Medicine Prince of Songkla University
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More information